RESUMO
Topicals and chemical peels are the standard of care for management of facial hyperpigmentation. However, traditional therapies have come under recent scrutiny, such as topical hydroquinone (HQ) has some regulatory restrictions, and high concentration trichloroacetic acid (TCA) peel pose a risk in patients with skin of colour. The objective of our research was to identify, investigate and elucidate the mechanism of action of a novel TCA- and HQ-free professional-use chemical peel to manage common types of facial hyperpigmentation. Using computational modelling and in vitro assays on tyrosinase, we identified proprietary multi-acid synergistic technology (MAST). After a single application on human skin explants, MAST peel was found to be more effective than a commercial HQ peel in inhibiting melanin (histochemical imaging and gene expression). All participants completed the case study (N = 9) without any adverse events. After administration of the MAST peel by a dermatologist, the scoring and VISIA photography reported improvements in hyperpigmentation, texture and erythema, which could be linked to underlying pathophysiological changes in skin after peeling, visualized by non-invasive optical biopsy of face. Using reflectance confocal microscopy (VivaScope®) and multiphoton tomography (MPTflex™), we observed reduction in melanin, increase in metabolic activity of keratinocytes, and no signs of inflammatory cells after peeling. Subsequent swabbing of the cheek skin found no microbiota dysbiosis resulting from the chemical peel. The strong efficacy with minimum downtime and no adverse events could be linked to the synergistic action of the ingredients in the novel HQ- and TCA-free professional peel technology.
Assuntos
Hidroquinonas , Hiperpigmentação , Melaninas , Humanos , Hiperpigmentação/tratamento farmacológico , Pele , Biologia Computacional , BiópsiaRESUMO
Hidradenitis suppurativa (HS) is a painful, disfiguring, chronic inflammatory disease affecting the axillary, inframammary, and groin regions. Black Americans are disproportionately affected by HS. Structural barriers may be responsible for a lack of better prevention and management. This paper discusses possible reasons that may lead to a more severe presentation and barriers to treatment. Moseley I, Ragi SD, Handler MZ. racial disparities in the treatment of hidradenitis suppurativa: an analysis of data from the National Ambulatory Medical Care Survey. J Drugs Dermatol. 2023;22(7):692-694. doi:10.36849/JDD.6803.
Assuntos
Hidradenite Supurativa , Humanos , Hidradenite Supurativa/terapia , Hidradenite Supurativa/tratamento farmacológico , Negro ou Afro-Americano , Pesquisas sobre Atenção à Saúde , Virilha , DorRESUMO
For decades, retinoids have been considered the gold standard of treatment for a variety of skin conditions.1,2 As the bioavailable form of vitamin A, retinoic acid has demonstrated the ability to reduce skin discoloration, stimulate collagen production, reduce rhytids, improve acne, and uneven skin texture.3,4 Retinoic acid is a potent drug with high bioavailability. Challenges with such a product include skin sensitivity and retinoid dermatitis.1,5 This potential irritation and discomfort may hinder patient compliance reducing visible results. The non-prescription vitamin A ingredient retinol is an effective and less irritating alternative, as it is converted into retinoic acid within the skin, causing little to no irritation when used topically. Intensive Age Refining Treatment: 0.5% pure retinol night by PCA SKIN® contains 0.5% retinol, protected and delivered into the skin with a multi-layered liposomal delivery technology. This development addresses the inherent instability of retinol,1,2,3 as well as the mitigation of irritation with the goal of enhancing patient compliance and visible results. This formulation also features niacinamide and terminalia chebula to further support the anti-aging benefits of retinol. The 12-week in vivo use of this potent, yet non-irritating retinol topical demonstrates improved patient compliance and satisfaction due to tolerability and enhanced efficacy in the improvement in overall signs of healthy skin. J Drugs Dermatol. 2022;21(7):784-788. doi:10.36849/JDD.6621.
Assuntos
Envelhecimento da Pele , Terminalia , Envelhecimento , Humanos , Niacinamida/efeitos adversos , Retinoides , Tretinoína/efeitos adversos , Vitamina A/efeitos adversosRESUMO
Neurofibromatosis type 1 is the most common neurocutaneous syndrome, with a frequency of 1 in 2500 persons. Diagnosis is paramount in the pretumor stage to provide proper anticipatory guidance for a number of neoplasms, both benign and malignant. Loss-of-function mutations in the NF1 gene result in truncated and nonfunctional production of neurofibromin, a tumor suppressor protein involved in downregulating the RAS signaling pathway. New therapeutic and preventive options include tyrosine kinase inhibitors, mTOR inhibitors, interferons, and radiofrequency therapy. This review summarizes recent updates in genetics, mutation analysis assays, and treatment options targeting aberrant genetic pathways. We also propose modified diagnostic criteria and provide an algorithm for surveillance of patients with neurofibromatosis type 1.
Assuntos
Neurofibromatose 1/diagnóstico , Neurofibromina 1/genética , Inibidores de Proteínas Quinases/uso terapêutico , Terapia por Radiofrequência/métodos , Neoplasias Cutâneas/genética , Terapia Combinada/métodos , Análise Mutacional de DNA , Diagnóstico Diferencial , Humanos , Mutação com Perda de Função , Neurofibromatose 1/genética , Neurofibromatose 1/terapia , Neurofibromina 1/metabolismo , Inibidores de Proteínas Quinases/farmacologia , Transdução de Sinais/genética , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/terapia , Serina-Treonina Quinases TOR/antagonistas & inibidores , Resultado do Tratamento , Proteínas ras/metabolismoRESUMO
BACKGROUND: No studies have examined the use of topical ingenol mebutate for improvement of photoaged skin. OBJECTIVE: To evaluate clinical results of ingenol mebutate gel applied to photoaged skin and to quantify improvement at 7, 30, and 60 days after application. MATERIALS AND METHODS: Twenty-five subjects were enrolled in the study. Picato (ingenol mebutate) (LEO Pharma, Parsippany, NJ) gel was applied to an area with a known actinic keratosis daily for 3 days. Subjects self-evaluated and were investigator evaluated on 6 characteristics on Days 7, 30, and 60 using an objective scale. The scale evaluated actinic keratosis, overall skin appearance, wrinkling, dyschromia, erythema, and texture. The subjects were also evaluated using the Griffiths' Photonumeric Photoaging Scale for overall improvement. RESULTS: Twenty-two subjects completed the clinical study and demonstrated statistically significant improvement by Day 60 in actinic keratosis, overall skin appearance, wrinkling, dyschromia, erythema, and texture (p < .05). CONCLUSION: Topical ingenol mebutate 0.015% gel produces cosmetic improvement of photoaged skin within 60 days of application.
Assuntos
Fármacos Dermatológicos/administração & dosagem , Diterpenos/administração & dosagem , Ceratose Actínica/tratamento farmacológico , Envelhecimento da Pele/efeitos dos fármacos , Idoso , Fármacos Dermatológicos/efeitos adversos , Diterpenos/efeitos adversos , Feminino , Géis , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Envelhecimento da Pele/efeitos da radiaçãoRESUMO
Patients with skin conditions may apply or consume a wide variety of "remedies" with a similarly wide range of effects that may alter the clinical and/or dermatologic presentations of the lesion. Dermatologists or other clinicians should probe for this and carefully document such treatment, as well as any treatment administered by a health care professional or any other person. The dermatopathologist, however, cannot assume that this has been done or done successfully, and therefore must be on constant alert to recognize the effects of such "remedies."
Assuntos
Erros de Diagnóstico , Autocuidado/efeitos adversos , Dermatopatias/patologia , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a rare genetic disorder that predisposes individuals to multiple cutaneous leiomyomas, renal cell carcinomas, and in women, uterine leiomyomas. Also known as Reed syndrome, it is caused by a germline heterozygous mutation of the fumarate hydratase tumor suppressor gene. HLRCC is associated with significant morbidity because of pain from cutaneous and uterine leiomyomas, the cutaneous pain often of unique character. Although genetic testing is currently considered the criterion standard to diagnose HLRCC, newer immunohistochemistry markers may provide rapid and cost effective alternatives to genetic testing. Because of the potentially aggressive nature of renal cell carcinomas that develop as early as in childhood, close annual cancer surveillance is desirable in individuals with HLRCC. In this review, we offer an update and an approach to the diagnosis, management, and renal cancer surveillance in HLRCC.
Assuntos
Leiomiomatose/diagnóstico , Leiomiomatose/terapia , Síndromes Neoplásicas Hereditárias/diagnóstico , Síndromes Neoplásicas Hereditárias/terapia , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/terapia , Neoplasias Uterinas/diagnóstico , Neoplasias Uterinas/terapia , Algoritmos , HumanosAssuntos
Lidocaína , Bicarbonato de Sódio , Anestésicos Locais , Custos e Análise de Custo , Epinefrina , HumanosRESUMO
BACKGROUND: Acne vulgaris is a chronic dermatologic complaint with a multifactorial cause. Traditionally, antibiotics and retinoids have been used to manage the condition; patient compliance has been an ongoing issue. A variety of energy-based devices have been reported to be effective in the treatment of acne vulgaris. OBJECTIVE: To review and summarize the current literature specific to treatment of acne vulgaris with energy-based devices. METHODS: A review of the current literature of energy-based devices used for the treatment of acne vulgaris. RESULTS AND CONCLUSIONS: Although limited randomized controlled trials for the treatment of acne have been performed, significant clinical improvement of acne vulgaris, especially of inflammatory lesions, has been demonstrated with a variety of energy-based devices. Newer approaches may lead to even better results.
Assuntos
Acne Vulgar/terapia , Fototerapia/métodos , Humanos , Fármacos Fotossensibilizantes/uso terapêuticoRESUMO
Human papillomavirus (HPV) affects hundreds of millions of people worldwide and is associated with both benign and malignant neoplasms in men and women. It is a double-stranded DNA virus with an icosahedral capsid. Forty HPV types are known to infect mucosal keratinocytes. If not cured by the immune system, the infection can lead to genital warts, mucosal dysplasia, or cancer. The most common oncogenic types are 16 and 18. The vaccine to prevent HPV and its associated morbidity and mortality has existed since 2006. Several variations protect against an increasing number of HPV types. The recommended vaccination age is before sexual exposure; administration of the vaccine to children has been controversial. This continuing medical education review evaluates the current HPV vaccines available to clinicians. Part I focuses on the debate over who should be vaccinated, at what age, and in which populations.
Assuntos
Vacinas contra Papillomavirus , Fatores Etários , Neoplasias do Ânus/prevenção & controle , Neoplasias do Ânus/virologia , Condiloma Acuminado/prevenção & controle , Condiloma Acuminado/virologia , Feminino , Homossexualidade Masculina , Humanos , Esquemas de Imunização , Masculino , Programas de Rastreamento , Transplante de Órgãos , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/prevenção & controle , Fatores de Risco , Comportamento Sexual , Estados Unidos/epidemiologia , Neoplasias do Colo do Útero/prevenção & controle , Neoplasias do Colo do Útero/virologiaRESUMO
As of December 2014, there were 3 approved vaccines for human papillomavirus (HPV): bivalent Cervarix (GlaxoSmithKline, New York, NY), quadrivalent Gardasil (Merck and Co, Kenilworth, NJ), and 9-valent Gardasil-9 (Merck and Co). The average cost per dose is $120, with a recommended 3-dose course. The quadrivalent vaccine is the most widely administered worldwide. As with the bivalent and 9-valent vaccines, the vaccine is considered safe, although concerns have been raised. In addition to immunization against the targeted HPV types, there is evidence that there is cross protection against other types of HPV. This continuing medical education review evaluates the differences in vaccines that are currently on the market; part II focuses on the cost-effectiveness of vaccination, the HPV vaccination programs currently instituted around the globe, efficacy, and safety.
Assuntos
Vacinas contra Papillomavirus , Fatores Etários , Condiloma Acuminado/prevenção & controle , Análise Custo-Benefício , Feminino , Humanos , Esquemas de Imunização , Programas Nacionais de Saúde , Neoplasias Orofaríngeas/prevenção & controle , Vacinas contra Papillomavirus/efeitos adversos , Vacinas contra Papillomavirus/economia , Neoplasias do Colo do Útero/prevenção & controle , Vacinação/efeitos adversos , Vacinação/economiaRESUMO
Leishmaniasis is endemic in 98 countries and territories, with 1.2 million new cases per year, making it a worldwide concern. The deadly visceral form is a leading cause of death from tropical parasitic infections, second only to malaria. Leishmaniasis appears to be increasing in many countries because of extended urbanization. The disease reservoir includes small mammals; parasite transmission occurs via bite of the female phlebotomine sandfly. Disease manifestations vary and largely depend upon the Leishmania species acquired. It may be first evident with a range of findings-from a localized cutaneous ulcer to diffuse painless dermal nodules-or, in the mucocutaneous form, ulceration of the oropharynx. In the potentially deadly visceral form, the internal organs and bone marrow are affected.
Assuntos
Leishmania donovani/isolamento & purificação , Leishmaniose Cutânea/diagnóstico , Leishmaniose Cutânea/epidemiologia , Leishmaniose Visceral/diagnóstico , Leishmaniose Visceral/epidemiologia , Animais , Antiprotozoários/uso terapêutico , Progressão da Doença , Doenças Endêmicas , Feminino , Humanos , Leishmaniose Cutânea/tratamento farmacológico , Leishmaniose Mucocutânea/diagnóstico , Leishmaniose Mucocutânea/tratamento farmacológico , Leishmaniose Mucocutânea/epidemiologia , Leishmaniose Visceral/tratamento farmacológico , Masculino , Prevalência , Prognóstico , Medição de Risco , Clima TropicalRESUMO
The diagnosis of leishmaniasis can be challenging because it mimics both infectious and malignant conditions. A misdiagnosis may lead to an unfavorable outcome. Using culture, histologic, and/or polymerase chain reaction study results, a diagnosis of leishmaniasis can be established and treatment initiated. Appropriate management requires an accurate diagnosis, which often includes identification of the specific etiologic species. Different endemic areas have varying sensitivities to the same medication, even within individual species. Species identification may be of practical value, because infections with select species have a substantial risk of visceral involvement. In addition, HIV and otherwise immunocompromised patients with leishmaniasis have a propensity for diffuse cutaneous leishmaniasis. For most New World Leishmania species, parenteral antimonial drugs remain the first line of therapy, while Old World species are easily treated with physical modalities. Historically, live organism vaccination has been used and is effective in preventing leishmaniasis, but results in an inoculation scar and an incubation period that may last for years. A more effective method of vaccination would be welcome.
Assuntos
Doenças Endêmicas , Hospedeiro Imunocomprometido , Leishmania/isolamento & purificação , Leishmaniose Cutânea/epidemiologia , Leishmaniose Cutânea/patologia , Anfotericina B/administração & dosagem , Animais , Antiprotozoários/uso terapêutico , Biópsia por Agulha , Quimioterapia Combinada , Feminino , Humanos , Imuno-Histoquímica , Incidência , Leishmaniose Cutânea/diagnóstico , Leishmaniose Cutânea/tratamento farmacológico , Leishmaniose Mucocutânea/tratamento farmacológico , Leishmaniose Mucocutânea/epidemiologia , Leishmaniose Mucocutânea/patologia , Masculino , Prognóstico , Medição de Risco , Resultado do Tratamento , Clima TropicalRESUMO
Striae distensae or stretch marks are a common skin condition that occurs frequently in association with adolescent growth spurts and pregnancy. They are characterized by linear symmetrical asymptomatic smooth bands of atrophic-appearing skin on the thighs, buttocks, and breasts in girls and on the shoulders, outer thighs, and lumbosacral areas in boys. We present a rare case of unilateral striae distensae affecting the right axilla in a 16-year-old boy.
Assuntos
Axila , Estrias de Distensão/diagnóstico , Adolescente , Humanos , MasculinoRESUMO
Hemimaxillary enlargement, asymmetry of the face, tooth abnormalities, and skin findings (HATS syndrome) is a rare developmental disorder involving the first and second branchial arches. Physical manifestations may present at birth or during early childhood. Characteristic findings include unilateral abnormalities of the face involving the bones, teeth, gums, and skin. Among the characteristic cutaneous manifestations of HATS syndrome, Becker nevus is the most common. A variety of modalities have been utilized in the treatment of HATS syndrome, but no standardized therapy has been established. We report a case of this rare condition in a 14-year-old adolescent boy.
Assuntos
Anormalidades Múltiplas , Hiperpigmentação , Terapia a Laser/métodos , Nevo , Neoplasias Cutâneas , Adolescente , Implantação Dentária , Diagnóstico Diferencial , Gerenciamento Clínico , Assimetria Facial/diagnóstico , Humanos , Hiperpigmentação/diagnóstico , Hiperpigmentação/terapia , Masculino , Maxila/anormalidades , Maxila/diagnóstico por imagem , Maxila/cirurgia , Nevo/patologia , Nevo/terapia , Procedimentos Cirúrgicos Ortognáticos/métodos , Radiografia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/terapia , Síndrome , Anormalidades Dentárias/diagnóstico , Anormalidades Dentárias/cirurgiaRESUMO
A 15-year-old Colombian boy with a 10-year history of linear morphea presented to a pediatric orthopedic clinic with a leg length discrepancy. The morphea had been previously treated with methotrexate, oral and topical steroids, and topical vitamin D, but the lesion persisted, extending down the entire medial aspect of the left leg across the popliteal fossa. The patient had atrophy and growth retardation of the left leg, resulting in lower extremity bone and joint pain and a 3-cm limb length disparity at maturity. The patient preferred left tibial lengthening to improve the limb length disparity.